CryoLife, Inc. (CRY)

HEALTH CARE: HEALTH CARE SERVICES
SIC: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

1655 ROBERTS BOULEVARD N W KENNESAW, GA 30144

CryoLife preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular applications. Co. distributes human tissue including the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch tissue, both processed using its proprietary SynerGraft technology. Co.'s surgical sealants and hemostats include BioGlue Surgical Adhesive, BioFoam Surgical Matrix, and PerClot, an absorbable powdered hemostat. Through its subsidiary Cardiogenesis Corporation, Co. provides treatment of coronary artery disease using a laser console system and single use, fiber-optic handpieces to treat patients with severe angina.

Data based on most recent fiscal year report
Market Cap655.816 Million Shares Outstanding33.46 Million Avg Volume233.635 Thousand
1-Yr BETA vs S&P TR Current Ratio4.18 Quick Ratio3.09
View SEC Filings from CRY instead.

View recent insider trading info

Funds Holding CRY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRY BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

10.4 Thousand total shares from 3 transactions

Exercise Derivative Conversion (M)

13.2 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HOLLOWAY JEAN F VP, GENERAL COUNSEL

  • Officer
59,059 2020-01-16 9

CAPPS SCOTT B VP, CLINICAL RESEARCH

  • Officer
143,895 2019-11-26 6

MCCALL RONALD D

  • Director
132,599 2019-11-19 5

MACKIN JAMES P PRESIDENT & CEO

  • Officer
225,731 2019-11-13 6

MORGAN HARVEY

  • Director
44,783 2019-11-06 2

GETZ MATTHEW A VP, HUMAN RESOURCES

  • Officer
0 2019-07-31 1

HORTON AMY VP, CHIEF ACCOUNTING OFFICER

  • Officer
99,329 2019-06-05 6

SALVESON JON W

  • Director
0 2019-05-23 1

BEVEVINO DANIEL J

  • Director
108,150 2019-05-16 1

ACKERMAN THOMAS F

  • Director
108,150 2019-05-16 1

BULLOCK JAMES

  • Director
17,067 2019-05-16 1

BURBANK JEFFREY H

  • Director
12,327 2019-05-16 1

BORGSTROM MARNA P

  • Director
7,619 2019-05-16 1

LEE DAVID ASHLEY EXECUTIVE VP, COO & CFO

  • Officer
282,065 2019-05-13 7

DAVIS JOHN E SENIOR VP, GLOBAL SALES

  • Officer
53,957 2019-03-14 4

SAURINI SHERRY M VP, QUALITY

  • Officer
25,084 2019-03-14 4

MCDERMID JAMES M SVP, CHRO

  • Officer
30,806 2019-03-14 3

MAIER DENNIS B VICE PRESIDENT, OPERATIONS

  • Officer
14,583 2019-03-14 2

BOGENSCHUETZ THOMAS J VP, EMEA & GENERAL MANAGER

  • Officer
20,615 2019-03-14 2

SIMPSON MICHAEL S SVP, REGULATORY AFFAIRS AND QA

  • Officer
15,523 2019-03-05 1

RONALD C ELKINS

  • Director
64,843 2018-09-05 0

MATTHEWS WILLIAM ROBERT SENIOR VP, OPERATIONS, QUALITY

  • Officer
39,883 2018-03-05 0

GALE DAVID C VP, RESEARCH & DEVELOPMENT

  • Officer
77,135 2017-11-16 0

BENSON JAMES

  • Director
54,086 2017-10-02 0

ANDERSON STEVEN G FORMER EXECUTIVE CHAIRMAN

  • Officer
No longer subject to file 2015-04-09 0

FRONK DAVID VP, REGULATORY AFFAIRS

  • Officer
110,559 2015-03-07 0

ANDERSON BRUCE G. VP, US SALES &GLOBAL MARKETING

  • Officer
104,096 2015-03-07 0

LANG DAVID P. VP, INT'L SALES & MARKETING

  • Officer
73,441 2015-02-26 0

BURRIS JEFFREY W VICE PRESIDENT & GEN. COUNSEL

  • Officer
95,221 2014-08-15 0

SEERY GERALD B SR. VP, SALES AND MARKETING

  • Officer
71,999 2012-11-30 0

HEACOX ALBERT E SR. VP RESEARCH AND DEVL

  • Officer
No longer subject to file 2011-12-31 0

COOK JOHN M

  • Director
104,500 2009-06-09 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

HOLLOWAY JEAN F - Officer VP, GENERAL COUNSEL

2020-01-16 M 195 $9.64 d 0 59,059.00 direct

HOLLOWAY JEAN F - Officer VP, GENERAL COUNSEL

2020-01-16 M 195 $9.64 a 59,059 59,059.00 direct

HOLLOWAY JEAN F - Officer VP, GENERAL COUNSEL

2020-01-16 S 195 $30.00 d 58,864 59,059.00 direct

HOLLOWAY JEAN F - Officer VP, GENERAL COUNSEL

2019-12-12 M 3,000 $10.24 a 13,236 58,864.00 direct

HOLLOWAY JEAN F - Officer VP, GENERAL COUNSEL

2019-12-12 S 3,000 $26.00 d 58,864 58,864.00 direct

HOLLOWAY JEAN F - Officer VP, GENERAL COUNSEL

2019-12-12 M 3,000 $10.24 a 61,864 58,864.00 direct

CAPPS SCOTT B - Officer VP, CLINICAL RESEARCH

2019-11-26 M 10,000 $6.12 a 151,079 143,895.00 direct

CAPPS SCOTT B - Officer VP, CLINICAL RESEARCH

2019-11-26 M 10,000 $6.12 d 0 143,895.00 direct

CAPPS SCOTT B - Officer VP, CLINICAL RESEARCH

2019-11-26 S 7,184 $24.93 d 143,895 143,895.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments